#USA #New York #Faruqi & Faruqi #ImmunityBio #IBRX

Faruqi & Faruqi Issues Urgent Notice to ImmunityBio Investors

As the deadline approaches for potential class action claims against ImmunityBio, Inc. (NASDAQ: IBRX), Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively encouraging affected investors to take necessary actions. The firm is investigating possible legal claims against ImmunityBio, which could impact investors who purchased or acquired its securities between January 19, 2026, and March 24, 2026.

Important Deadline

The firm is reminding investors that the deadline to seek a role as a lead plaintiff in the federal securities class action lawsuit is set for May 26, 2026. This announcement aims to ensure that investors who may have sustained losses have the chance to explore their legal rights.

Background Information

The allegations regarding ImmunityBio stem from a failure to disclose critical information affecting the company's stock performance. Specifically, the complaint asserts that ImmunityBio, under the guidance of its executives, including Patrick Soon-Shiong, misrepresented the capabilities of its drug Anktiva, which has significant implications for investor trust.

On January 23, 2026, ImmunityBio unveiled updated Phase 2 clinical trial results for its treatment of patients suffering from recurrent glioblastoma. The press release disclosed that the primary endpoint of the trial—median overall survival—had not been reached. This announcement resulted in a notable decline of ImmunityBio's stock price, plummeting to $6.45 per share after a decrease of over 12%.

The Role of the Lead Plaintiff

In a class action lawsuit, the court appoints a lead plaintiff who represents the collective interests of all class members. This individual is characterized by having the largest financial stake in the outcome and must demonstrate a typical representation of the group’s interests. Observers highlight that whether an individual opts to step forward as a lead plaintiff will not influence their potential recovery if they remain part of the class.

Call to Action

Faruqi & Faruqi, LLP is now inviting investors who believe they may have information regarding ImmunityBio's practices—whistleblowers, former employees, or shareholders—to reach out. This information is crucial in developing a robust case against the company and could aid significantly in maximizing potential recovery for affected investors.

For those interested in learning more about this class action lawsuit or seeking guidance on how to proceed, they are encouraged to visit Faruqi & Faruqi's website or directly contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

As the May 26 deadline looms closer, it is imperative for ImmunityBio investors to evaluate their legal options regarding the recent actions of the company. Affected parties should not hesitate to seek counsel and understand their rights during this crucial period. Faruqi & Faruqi, LLP continues to advocate for investors and remains a leading resource in navigating the complexities of securities litigation.